Quantitative analysis for CytomX Therapeutics, Inc. (CTMX) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Sell (39.0) (grade D). Gem alpha score: 50.0. 28 signals analyzed (23 differentiated alt-data).
CTMX stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-29 | $4.14 | $4.00 | $4.05 |
| 2026-05-11 | $4.12 | $3.81 | $3.86 |
| 2026-05-21 | $3.80 | $3.64 | $3.76 |
| 2026-06-03 | $3.31 | $3.17 | $3.22 |
| 2026-06-15 | $3.13 | $2.98 | $3.04 |
| 2026-06-26 | $3.48 | $3.23 | $3.40 |
| 2026-07-09 | $3.96 | $3.77 | $3.96 |
| 2026-07-21 | $3.55 | $3.39 | $3.42 |
| 2026-07-31 | $3.28 | $3.10 | $3.10 |
| 2026-08-12 | $3.54 | $3.42 | $3.49 |
| 2026-08-24 | $3.38 | $3.18 | $3.29 |
| 2026-09-03 | $3.82 | $3.61 | $3.68 |
How CytomX Therapeutics, Inc. stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| BWAY | BrainsWay Ltd. | $599M | — |
| ANL | Adlai Nortye Ltd. | $603M | 41.0 |
| TLRY | Tilray Brands, Inc. | $647M | — |
| PROK | ProKidney Corp. | $545M | — |
View all Health Care stocks by valuation and signals →
CytomX Therapeutics, Inc. (CTMX) scores Sell (39.0), and the composite conceals a 85-point disagreement between its dimensions. It is strongest on analyst consensus at 94 and competitive moat at 62, and weakest on technicals at 9. A stock can carry analyst consensus that high while technicals sits at 9; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| analyst consensus | 94 |
| competitive moat | 62 |
| AI Alpha (gem) | 57 |
| ML forecast | 45 |
| technicals | 9 |
StoQuant analyzes 28 signals (23 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on CytomX Therapeutics, Inc. (CTMX): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/CTMX"><img src="https://stoquant.com/badge/CTMX.svg" alt="CytomX Therapeutics, Inc. (CTMX) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.